Heartbeam, Inc. · NASDAQ:BEAT

Heartbeam — Q1 2025 Earnings Presentation

13 slides from Heartbeam's earnings presentation, May 13, 2025

  1. Slide 1: The Future of Cardiac Care

    The Future of Cardiac Care First Quarter 2025 Financial Results Conference Call NASDAQ: BEAT MAY 13, 2025

  2. Slide 2: Disclaimers

    First Quarter 2025 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position

  3. Slide 3: Agenda: On the Call Today

    First Quarter 2025 Financial Results Conference Call Agenda: On the Call Today: HEARTBEAM SYSTEM COMPANY MILESTONES VALID-ECG DATA ACCURKARDIA COLLABORATION Rob Eno Tim Cruickshank COMMERCIAL READINESS CEO CFO LONG TERM VALUE FINANCIAL RESULTS 3

  4. Slide 4: Overview of the HeartBeam System

    First Quarter 2025 Financial Results Conference Call Overview of the HeartBeam System FOUNDATIONAL FDA CLEARANCE • Received December 2024 • HeartBeam System: the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non- co-planar directions, for arrhythmia assessment 12-LEAD

  5. Slide 5: Key Developments Since Last Update

    First Quarter 2025 Financial Results Conference Call Key Developments Since Last Update • Pivotal study successfully met clinical endpoints CLINICAL • VALID-ECG results for 12-lead ECG Synthesis presented at HRS 2025 EVIDENCE • Study formed basis for FDA 510(k) application submitted for 12-lead ECG

  6. Slide 6: Continued Achievement of Stated Milestones

    First Quarter 2025 Financial Results Conference Call COMPANY MILESTONES Continued Achievement of Stated Milestones 2024 2025 Regulatory Clinical Commercial HeartBeam System FDA Clearance Foundational Clearance VALID-ECG FDA Clearance FDA 510(k) Submission 12-Lead Synthesis Software Enrollment Comple

  7. Slide 7: VALID-ECG Pivotal Study Successfully Met Clinical Endpoints

    First Quarter 2025 Financial Results Conference Call CLINICAL EVIDENCE VALID-ECG Pivotal Study Successfully Met Clinical Endpoints Study formed the basis of 12L ECG synthesis submission • Simultaneously recorded 12-lead ECGs: Standard and HeartBeam Synthesized • Enrolled 198 patients with sinus rhyt

  8. Slide 8: Strategic Collaboration with AccurKardia

    First Quarter 2025 Financial Results Conference Call Strategic Collaboration with AccurKardia • Add AccurKardia’s AccurECGTM algorithm to Focus of HeartBeam’s devices Collaboration • Provide an automated arrhythmia assessment • Innovator in ECG-based diagnostics technology to facilitate a quicker di

  9. Slide 9: Executing on Commercial Readiness Plans

    First Quarter 2025 Financial Results Conference Call GO TO MARKET STRATEGY Executing on Commercial Readiness Plans • Early Access Program commenced in Q1’25 • Testing with concierge accounts and patients • Feedback on the offering, workflow, real world usage data • Building commercial infrastructure

  10. Slide 10: HeartBeam Positioned for Long-Term Value Creation

    First Quarter 2025 Financial Results Conference Call HeartBeam Positioned for Long-Term Value Creation STRONG IP INITIAL MARKET HEART ATTACK REIMBURSEMENT OPEN-ENDED AND HOLDS DETECTION AND PAYMENT LONG-TERM DE-RISKED SIGNIFICANT OPENS HUGE BEYOND PATIENT OPPORTUNITY TECHNOLOGY PROMISE OPPORTUNITY P

  11. Slide 11: Financial Discipline Aligned to Achieving Milestones

    First Quarter 2025 Financial Results Conference Call FINANCIAL RESULTS Financial Discipline Aligned to Achieving Milestones • Net cash used in operating activities of $4.5M $ in Thousands​ Quarter Ended Quarter Ended Quarter Ended March 31,​ for Q1 FY’25, an 8% increase quarter-over- March 31, 2025

  12. Slide 12: HeartBeam: Q1 2025 Summary

    First Quarter 2025 Financial Results Conference Call HeartBeam: Q1 2025 Summary • VALID-ECG pivotal study successfully met clinical endpoints for arrhythmia assessment CLINICAL AND • Productive discussions with FDA on 12-lead ECG Synthesis submission for arrhythmia REGULATORY assessment PROGRESS • C

  13. Slide 13: Company Investor Relations

    Q&A Company Investor Relations Tim Cruickshank Chris Tyson CFO Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050

Heartbeam — Q1 2025 Earnings Presentation on 6ix